CompletedNCT01846052
Clinical and Genetic Characterization of Individuals With Achromatopsia
Studying Achromatopsia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beacon Therapeutics
- Principal Investigator
- Matt Feinsod, MDApplied Genetics Technologies Corporation
- Enrollment
- 56 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2013 – 2017
Study locations (5)
- VitreoRetinal Associates, Gainesville, Florida, United States
- Bascom Palmer Eye Institute, Miami, Florida, United States
- Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp, Chicago, Illinois, United States
- Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Collaborators
National Eye Institute (NEI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01846052 on ClinicalTrials.govOther trials for Achromatopsia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07085533Natural History Study of Inherited Retinal DiseasesZhongmou Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02935517Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02610582Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked AchromatopsiaSTZ eyetrial